High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis

M. H. Imam, E. Sinakos, A. A. Gossard, K. V. Kowdley, V. A C Luketic, M. Edwyn Harrison, T. McCashland, A. S. Befeler, Denise Harnois, R. Jorgensen, J. Petz, J. Keach, A. C. Decook, Felicity T Enders, K. D. Lindor

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Background Ursodeoxycholic acid (UDCA) in a dose of 28-30 mg/kg/day increases the likelihood of clinical deterioration of primary sclerosing cholangitis (PSC) patients. Aim To compare the risk of adverse clinical endpoints in patients with varying disease status. Methods We reviewed records from patients previously enrolled in a study evaluating the effects of high dose (28-30 mg/kg/day) UDCA in PSC. Patients were grouped according to treatment (UDCA vs. placebo) and baseline disease status (histological stage of PSC, total serum bilirubin). Development of clinical endpoints including death, liver transplantation, cirrhosis, oesophageal varices and cholangiocarcinoma was sought. Results A total of 150 patients were included of whom 49 patients developed endpoints. There was an increased development of endpoints among patients using UDCA vs. placebo (14 vs. 4, P = 0.0151) with early histological disease (stage 1-2, n = 88) but not with late stage (stage 3-4, n = 62) disease (17 vs. 14, P = 0.2031). Occurrence of clinical endpoints was also higher in patients receiving UDCA vs. placebo (16 vs. 2, P = 0.0008) with normal bilirubin levels (total bilirubin ≥1.0 mg/dL) but not in patients with elevated bilirubin levels (15 vs. 16, P = 0.6018). Among patients not reaching endpoints 31.7% had normalisation of their alkaline phosphatase levels when compared to 14.3% in patients who reached endpoints (P = 0.073). Conclusion The increased risk of adverse events with UDCA treatment when compared with placebo is only apparent in patients with early histological stage disease or normal total bilirubin.

Original languageEnglish (US)
Pages (from-to)1185-1192
Number of pages8
JournalAlimentary Pharmacology and Therapeutics
Volume34
Issue number10
DOIs
StatePublished - Nov 2011

Fingerprint

Ursodeoxycholic Acid
Sclerosing Cholangitis
Bilirubin
Placebos
Cholangiocarcinoma
Esophageal and Gastric Varices
Liver Cirrhosis
Liver Transplantation
Alkaline Phosphatase

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Imam, M. H., Sinakos, E., Gossard, A. A., Kowdley, K. V., Luketic, V. A. C., Edwyn Harrison, M., ... Lindor, K. D. (2011). High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Alimentary Pharmacology and Therapeutics, 34(10), 1185-1192. https://doi.org/10.1111/j.1365-2036.2011.04863.x

High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. / Imam, M. H.; Sinakos, E.; Gossard, A. A.; Kowdley, K. V.; Luketic, V. A C; Edwyn Harrison, M.; McCashland, T.; Befeler, A. S.; Harnois, Denise; Jorgensen, R.; Petz, J.; Keach, J.; Decook, A. C.; Enders, Felicity T; Lindor, K. D.

In: Alimentary Pharmacology and Therapeutics, Vol. 34, No. 10, 11.2011, p. 1185-1192.

Research output: Contribution to journalArticle

Imam, MH, Sinakos, E, Gossard, AA, Kowdley, KV, Luketic, VAC, Edwyn Harrison, M, McCashland, T, Befeler, AS, Harnois, D, Jorgensen, R, Petz, J, Keach, J, Decook, AC, Enders, FT & Lindor, KD 2011, 'High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis', Alimentary Pharmacology and Therapeutics, vol. 34, no. 10, pp. 1185-1192. https://doi.org/10.1111/j.1365-2036.2011.04863.x
Imam, M. H. ; Sinakos, E. ; Gossard, A. A. ; Kowdley, K. V. ; Luketic, V. A C ; Edwyn Harrison, M. ; McCashland, T. ; Befeler, A. S. ; Harnois, Denise ; Jorgensen, R. ; Petz, J. ; Keach, J. ; Decook, A. C. ; Enders, Felicity T ; Lindor, K. D. / High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. In: Alimentary Pharmacology and Therapeutics. 2011 ; Vol. 34, No. 10. pp. 1185-1192.
@article{2f626268be114ddebe9f23cc2f643ffe,
title = "High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis",
abstract = "Background Ursodeoxycholic acid (UDCA) in a dose of 28-30 mg/kg/day increases the likelihood of clinical deterioration of primary sclerosing cholangitis (PSC) patients. Aim To compare the risk of adverse clinical endpoints in patients with varying disease status. Methods We reviewed records from patients previously enrolled in a study evaluating the effects of high dose (28-30 mg/kg/day) UDCA in PSC. Patients were grouped according to treatment (UDCA vs. placebo) and baseline disease status (histological stage of PSC, total serum bilirubin). Development of clinical endpoints including death, liver transplantation, cirrhosis, oesophageal varices and cholangiocarcinoma was sought. Results A total of 150 patients were included of whom 49 patients developed endpoints. There was an increased development of endpoints among patients using UDCA vs. placebo (14 vs. 4, P = 0.0151) with early histological disease (stage 1-2, n = 88) but not with late stage (stage 3-4, n = 62) disease (17 vs. 14, P = 0.2031). Occurrence of clinical endpoints was also higher in patients receiving UDCA vs. placebo (16 vs. 2, P = 0.0008) with normal bilirubin levels (total bilirubin ≥1.0 mg/dL) but not in patients with elevated bilirubin levels (15 vs. 16, P = 0.6018). Among patients not reaching endpoints 31.7{\%} had normalisation of their alkaline phosphatase levels when compared to 14.3{\%} in patients who reached endpoints (P = 0.073). Conclusion The increased risk of adverse events with UDCA treatment when compared with placebo is only apparent in patients with early histological stage disease or normal total bilirubin.",
author = "Imam, {M. H.} and E. Sinakos and Gossard, {A. A.} and Kowdley, {K. V.} and Luketic, {V. A C} and {Edwyn Harrison}, M. and T. McCashland and Befeler, {A. S.} and Denise Harnois and R. Jorgensen and J. Petz and J. Keach and Decook, {A. C.} and Enders, {Felicity T} and Lindor, {K. D.}",
year = "2011",
month = "11",
doi = "10.1111/j.1365-2036.2011.04863.x",
language = "English (US)",
volume = "34",
pages = "1185--1192",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis

AU - Imam, M. H.

AU - Sinakos, E.

AU - Gossard, A. A.

AU - Kowdley, K. V.

AU - Luketic, V. A C

AU - Edwyn Harrison, M.

AU - McCashland, T.

AU - Befeler, A. S.

AU - Harnois, Denise

AU - Jorgensen, R.

AU - Petz, J.

AU - Keach, J.

AU - Decook, A. C.

AU - Enders, Felicity T

AU - Lindor, K. D.

PY - 2011/11

Y1 - 2011/11

N2 - Background Ursodeoxycholic acid (UDCA) in a dose of 28-30 mg/kg/day increases the likelihood of clinical deterioration of primary sclerosing cholangitis (PSC) patients. Aim To compare the risk of adverse clinical endpoints in patients with varying disease status. Methods We reviewed records from patients previously enrolled in a study evaluating the effects of high dose (28-30 mg/kg/day) UDCA in PSC. Patients were grouped according to treatment (UDCA vs. placebo) and baseline disease status (histological stage of PSC, total serum bilirubin). Development of clinical endpoints including death, liver transplantation, cirrhosis, oesophageal varices and cholangiocarcinoma was sought. Results A total of 150 patients were included of whom 49 patients developed endpoints. There was an increased development of endpoints among patients using UDCA vs. placebo (14 vs. 4, P = 0.0151) with early histological disease (stage 1-2, n = 88) but not with late stage (stage 3-4, n = 62) disease (17 vs. 14, P = 0.2031). Occurrence of clinical endpoints was also higher in patients receiving UDCA vs. placebo (16 vs. 2, P = 0.0008) with normal bilirubin levels (total bilirubin ≥1.0 mg/dL) but not in patients with elevated bilirubin levels (15 vs. 16, P = 0.6018). Among patients not reaching endpoints 31.7% had normalisation of their alkaline phosphatase levels when compared to 14.3% in patients who reached endpoints (P = 0.073). Conclusion The increased risk of adverse events with UDCA treatment when compared with placebo is only apparent in patients with early histological stage disease or normal total bilirubin.

AB - Background Ursodeoxycholic acid (UDCA) in a dose of 28-30 mg/kg/day increases the likelihood of clinical deterioration of primary sclerosing cholangitis (PSC) patients. Aim To compare the risk of adverse clinical endpoints in patients with varying disease status. Methods We reviewed records from patients previously enrolled in a study evaluating the effects of high dose (28-30 mg/kg/day) UDCA in PSC. Patients were grouped according to treatment (UDCA vs. placebo) and baseline disease status (histological stage of PSC, total serum bilirubin). Development of clinical endpoints including death, liver transplantation, cirrhosis, oesophageal varices and cholangiocarcinoma was sought. Results A total of 150 patients were included of whom 49 patients developed endpoints. There was an increased development of endpoints among patients using UDCA vs. placebo (14 vs. 4, P = 0.0151) with early histological disease (stage 1-2, n = 88) but not with late stage (stage 3-4, n = 62) disease (17 vs. 14, P = 0.2031). Occurrence of clinical endpoints was also higher in patients receiving UDCA vs. placebo (16 vs. 2, P = 0.0008) with normal bilirubin levels (total bilirubin ≥1.0 mg/dL) but not in patients with elevated bilirubin levels (15 vs. 16, P = 0.6018). Among patients not reaching endpoints 31.7% had normalisation of their alkaline phosphatase levels when compared to 14.3% in patients who reached endpoints (P = 0.073). Conclusion The increased risk of adverse events with UDCA treatment when compared with placebo is only apparent in patients with early histological stage disease or normal total bilirubin.

UR - http://www.scopus.com/inward/record.url?scp=80055025463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055025463&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2011.04863.x

DO - 10.1111/j.1365-2036.2011.04863.x

M3 - Article

C2 - 21957881

AN - SCOPUS:80055025463

VL - 34

SP - 1185

EP - 1192

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 10

ER -